Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioRestorative Therapies's enterprise value is €-5.92 Mil.
BioRestorative Therapies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-12.04 Mil. Therefore, BioRestorative Therapies's EV-to-EBITDA for today is 0.49.
The historical rank and industry rank for BioRestorative Therapies's EV-to-EBITDA or its related term are showing as below:
FRA:9OF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.91 Med: -0.69 Max: 0.64
Current: 0.47
During the past 13 years, the highest EV-to-EBITDA of BioRestorative Therapies was 0.64. The lowest was -11.91. And the median was -0.69.
FRA:9OF's EV-to-EBITDA is ranked better than 84.63% of 410
companies
in the Biotechnology industry
Industry Median: 11.46
vs FRA:9OF: 0.47
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioRestorative Therapies's PE Ratio (TTM) for today is calculated as:
BioRestorative Therapies's share price for today is €0.232.
BioRestorative Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.918.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9OF vs LIMN, BOLT, TRAW: EV-to-EBITDA Comparison
For the Biotechnology subindustry, BioRestorative Therapies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's EV-to-EBITDA falls into.
BioRestorative Therapies's current Enterprise Value is €-5.92 Mil.
BioRestorative Therapies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (FRA:9OF) has a EV-to-EBITDA of 0.49 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioRestorative Therapies. According to the industry distribution chart, BioRestorative Therapies ranks #63 out of 410 companies in the Biotechnology industry, placing it in the top 15.4%.
Is BioRestorative Therapies' EV-to-EBITDA too high?
BioRestorative Therapies' current EV-to-EBITDA is 0.49. The Biotechnology industry median EV-to-EBITDA is 11.46. BioRestorative Therapies' value of 0.49 is 95.7% below this industry median. Based on the distribution chart, BioRestorative Therapies ranks #63 out of 410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' EV-to-EBITDA compare to LIMN and BOLT?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #63 out of 410 companies for EV-to-EBITDA. This places BioRestorative Therapies in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 11.46. BioRestorative Therapies' value of 0.49 is 95.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.46, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current EV-to-EBITDA of 0.49 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioRestorative Therapies. For the Biotechnology industry, the median EV-to-EBITDA is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current EV-to-EBITDA is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.40, compared to a current price of €0.23 — trading 83.4% below its estimated fair value. The current EV-to-EBITDA is 0.49 and 95.7% below the Biotechnology industry median of 11.46. BioRestorative Therapies' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current EV-to-EBITDA is 0.49 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.23 is trading 83.4% below its estimated GF Value™ of €1.40.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
EV-to-EBITDA: 0.49
GF Value™: €1.40 vs. price of €0.23 (83.4% below fair value)
Industry Position: 95.7% below the Biotechnology median (#63 of 410)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
55GF Score
Get the complete analysis for FRA:9OF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
